Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis.

Pharmacokinetic and chemotherapeutic studies have been carried out with aerosolised alginate nanoparticles encapsulating isoniazid (INH), rifampicin (RIF) and pyrazinamide (PZA). The nanoparticles were prepared by cation-induced gelification of alginate and were 235.5 +/- 0 nm in size, with drug encapsulation efficiencies of 70-90% for INH and PZA and 80-90% for RIF. The majority of particles (80.5%) were in the respirable range, with mass median aerodynamic diameter of 1.1 +/- 0.4 microm and geometric standard deviation of 1.71 +/- 0.1 microm. The relative bioavailabilities of all drugs encapsulated in alginate nanoparticles were significantly higher compared with oral free drugs. All drugs were detected in organs (lungs, liver and spleen) above the minimum inhibitory concentration until 15 days post nebulisation, whilst free drugs stayed up to day 1. The chemotherapeutic efficacy of three doses of drug-loaded alginate nanoparticles nebulised 15 days apart was comparable with 45 daily doses of oral free drugs. Thus, inhalable alginate nanoparticles can serve as an ideal carrier for the controlled release of antitubercular drugs.

[1]  E. Scott,et al.  Fluorometric determination of isonicotinic acid hydrazide in serum. , 1967, The Journal of laboratory and clinical medicine.

[2]  R. Müller,et al.  Production and Characterization of a Budesonide Nanosuspension for Pulmonary Administration , 2002, Pharmaceutical Research.

[3]  Rajesh Pandey,et al.  Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. , 2003, The Journal of antimicrobial chemotherapy.

[4]  R. Reves,et al.  Noncompliance with directly observed therapy for tuberculosis. Epidemiology and effect on the outcome of treatment. , 1997, Chest.

[5]  R. Pandey,et al.  Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes. , 2002, International journal of antimicrobial agents.

[6]  H. Tønnesen,et al.  Alginate in Drug Delivery Systems , 2002, Drug development and industrial pharmacy.

[7]  Indu Bala,et al.  PLGA nanoparticles in drug delivery: the state of the art. , 2004, Critical reviews in therapeutic drug carrier systems.

[8]  Kevin Y. Lin,et al.  Biodegradable polyphosphoester micelles for gene delivery. , 2004, Journal of pharmaceutical sciences.

[9]  H. Tomioka,et al.  Therapeutic efficacy of liposome-entrapped rifampin against Mycobacterium avium complex infection induced in mice , 1989, Antimicrobial Agents and Chemotherapy.

[10]  R. Pandey,et al.  Chemotherapeutic potential of alginate-chitosan microspheres as anti-tubercular drug carriers. , 2004, The Journal of antimicrobial chemotherapy.

[11]  A. Misra,et al.  Development of Liposomal Amphotericin B Dry Powder Inhaler Formulation , 2004, Drug delivery.

[12]  S. Lehnert,et al.  A novel non-toxic camptothecin formulation for cancer chemotherapy. , 2005, Biomaterials.

[13]  P Couvreur,et al.  Development of a new drug carrier made from alginate. , 1993, Journal of pharmaceutical sciences.

[14]  S. Garg,et al.  Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects. , 2003, The Journal of antimicrobial chemotherapy.

[15]  R. Pandey,et al.  Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. , 2003, Tuberculosis.

[16]  N. G. Nair,et al.  Methods for the estimation of pyrazinamide and pyrazinoic acid in body fluids. , 1980, The Indian journal of medical research.